🔗 Share this article

The recently developed medications for gonorrhoea in many years are being described as a "major milestone" in the effort against superbug strains of the infection, according to researchers.

An International Health Concern

Cases of gonorrhoea are increasing around the world, with figures suggesting over 82 million instances each year. Especially elevated rates are observed in the African continent and nations within the WHO's designated area, which includes China and Mongolia to New Zealand. In England, cases have hit a all-time high, while infection numbers across Europe in 2023 were triple the level compared to the rates from 2014.

“The approval of novel therapies for gonorrhoea is an significant and necessary step in the face of increasing worldwide cases, increasing antimicrobial resistance and the highly restricted treatment choices at this time.”

Health officials are increasingly worried about the rise in drug-resistant strains. The WHO has classified it as a "critical concern". A tracking program showed that resistance to standard treatments like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Two New Drugs Receive Clearance

One new antibiotic, alternatively called a brand name, was authorized by the US FDA in mid-December for use against gonorrhoea. This disease can lead to serious health problems, including infertility. Scientists hope that specific application of this new drug will help hinder the development of resistance.

Another new antibiotic, developed by the drugmaker GlaxoSmithKline, gained clearance in the same week. This drug, which is employed against urinary tract infections, was shown in trials to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

An Innovative Development Model

Zoliflodacin stemmed from a innovative non-profit model for medication research. The non-profit organisation GARDP worked alongside the drug firm Innoviva to develop it.

“This authorization represents a significant shift in the treatment of superbug gonorrhoea, which up to this point has been evolving faster than our drug pipeline.”

Clinical Trial Data and Global Access

Based on results released by a prominent scientific publication, the new drug cured more than 90% of uncomplicated infections. This establishes an similar efficacy with the current standard treatment, which combines an injection and a pill. The study included nearly 1,000 volunteers from various regions including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its unique model, the non-profit has the rights to license and sell the drug in numerous developing nations.

Doctors directly involved have voiced optimism. Having a easy-to-administer therapy of this kind is hailed as a "game-changer" for gonorrhoea control. This is deemed crucial to lessen the impact of the disease for people and to halt the transmission of extremely resistant gonorrhoea around the world.